Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Medpace Holdings Inc    MEDP

MEDPACE HOLDINGS INC

(MEDP)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Medpace Holdings, Inc. : to Report Second Quarter 2019 Financial Results on July 29, 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/25/2019 | 04:06pm EDT

Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its second quarter 2019 financial results after the market close on Monday, July 29, 2019. The Company will host a conference call the following morning, Tuesday, July 30, 2019, at 9:00 a.m. ET to discuss these results.

To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 6197355.

To access the conference call via webcast, visit the “Investors” section of Medpace’s website at investor.medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A supplemental slide presentation will also be available at the “Investors” section of Medpace’s website prior to the start of the call.

A recording of the call will be available from 12:00 p.m. ET on Tuesday, July 30, 2019 until 12:00 p.m. ET on Tuesday, August 13, 2019. To hear this recording, dial 855-859-2056 (domestic) or 404-537-3406 (international) using the passcode 6197355.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 3,100 people across 37 countries.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDPACE HOLDINGS INC
06/25MEDPACE HOLDINGS, INC. : to Report Second Quarter 2019 Financial Results on July..
BU
05/24MEDPACE HOLDINGS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
05/21MEDPACE HOLDINGS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
05/21MEDPACE HOLDINGS, INC. : to Present at Jefferies 2019 Healthcare Conference
BU
05/17MEDPACE HOLDINGS, INC. : Submission of Matters to a Vote of Security Holders (fo..
AQ
05/08109,719 Shares in Medpace Holdings Inc (MEDP) Acquired by Norris Perne & Fren..
AQ
04/30MEDPACE : Management's Discussion and Analysis of Financial Condition and Result..
AQ
04/29MEDPACE : 1Q Earnings Snapshot
AQ
04/29MEDPACE HOLDINGS, INC. : Results of Operations and Financial Condition, Financia..
AQ
04/29MEDPACE HOLDINGS, INC. : Reports First Quarter 2019 Results
BU
More news
Financials (USD)
Sales 2019 827 M
EBIT 2019 129 M
Net income 2019 90,1 M
Finance 2019 39,8 M
Yield 2019 -
P/E ratio 2019 26,4x
P/E ratio 2020 22,8x
EV / Sales2019 2,69x
EV / Sales2020 2,26x
Capitalization 2 261 M
Chart MEDPACE HOLDINGS INC
Duration : Period :
Medpace Holdings Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDPACE HOLDINGS INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 61,00  $
Last Close Price 63,47  $
Spread / Highest target 2,41%
Spread / Average Target -3,89%
Spread / Lowest Target -13,3%
EPS Revisions
Managers
NameTitle
August James Troendle Chairman, President & Chief Executive Officer
Susan E. Burwig Executive Vice President-Operations
Jesse J. Geiger CFO & COO-Laboratory Operations
Daniel O’Leary Senior Vice President-Medical Affairs
Yun Le Vice President-Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
MEDPACE HOLDINGS INC19.91%2 228
IQVIA HOLDINGS INC36.35%31 409
LONZA GROUP30.00%25 111
CELLTRION, INC.--.--%20 827
INCYTE CORPORATION27.99%17 419
EXACT SCIENCES CORPORATION84.14%15 001